Abstract
Purpose
The aim of this study was to evaluate the clinical usefulness of scintigraphy with 99mTc-depreotide in the assessment of loco-regional nodal spread in patients with suspected lung cancer in comparison with computed tomography (CT).
Methods
Eighty-six patients were investigated with single-photon emission computed tomography (SPECT) of the thorax after i.v. injection of 740 MBq 99mTc-depreotide. The results were evaluated in conjunction with a thoracic CT scan in all 86 patients with 204 lymph node stations. The scintigraphic results were correlated with cytological (38), histological (20) or clinical–radiological (146) findings and compared with CT. The quantitative evaluation of depreotide uptake was performed on 48 cytologically or histologically verified nodal stations from 28 patients by SPECT using region of interest analysis with four different reference regions.
Results
99mTc-depreotide scintigraphy for all 204 investigated lymph node stations had a sensitivity of 99% and a negative predictive value of 98% in determining lymph node involvement. Scintigraphy and CT showed the same level of accuracy, 76.4%. CT findings had a higher positive predictive value but a lower negative predictive value compared to 99mTc-depreotide scintigraphy. The quantitative evaluation of depreotide uptake in lymph nodes using vertebra as a reference region showed that a cut-off level of 0.56 excludes malignant involvement of lymph nodes, while a cut-off level of 1.66 excludes benign disease in lymph nodes. About 73% of all investigated lymph node stations showed uptake values between these cut-off levels.
Conclusion
Absence of 99mTc-depreotide uptake on scintigraphic imaging can exclude regional lymph node involvement with a high degree of probability and may be useful in clinical practice. The quantitative evaluation of depreotide uptake in regional lymph nodes did not increase the diagnostic accuracy of the method in general but did elucidate the lymph node status in some patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710–7.
Webb WR, Catsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705–13.
Ho Shon I, O’ Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nuclear Med 2003;XXXII(4):240–71.
Blum J, Handmaker H, Lister-James J, Rinne N, NeoTect Solitary Pulmonary Nodule Study Group. A multicenter trial with a somatostatin analog 99m-Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232–8.
Reubi JC, Laissue J, Krenning EP, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical application. J Steroid Biochem Mol Biol 1992;43:27–35.
O’Byrne KJ, Carney DN. Somatostatin and the lung. Lung Cancer 1993;10:151–72.
Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specificity and in vitro binding of a novel tumour tracer, 99mTc-P829. Cancer Res 1998;58:1850–9.
Menda Y, Kahn D, Bushnell DL, Thomas M, Miller S, McLaughlin K, et al. Non-specific mediastinal uptake of 99m-Tc depreotide (NeoTect™). J Nucl Med 2001;42:304P.
Grewal RK, Dadparvar S, Yu JQ, Babaria CJ, Cavanaugh T, Sherman M, et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002;8(5):400–4.
Tcherniantchouk O, Waxman AD, Williams CM, Kononov Y, Alsabeh R, ’Agnolo D, et al. Evaluation of hilar and mediastinal lymph nodes with Tc-99m depreotide in lung cancer: detection of micrometastases. J Nucl Med 2003;44:Suppl, abstract 440.
Kahn D, Menda Y, Kernstine K, Bushnell D, McLaughlin K, Miller S, et al. The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494–501.
Menda Y, Khan D. Somatostatin receptor imaging of non-small cell lung cancer with 99m-Tc depreotide. Semin Nucl Med 2002;XXXII:92–6.
DeVita VT, Hellman S, Rosemberg SA. Cancer. Principles and practice of oncology. Philadelphia: J.B. Lippincott; 1982.
Van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Löwenberg B, et al. Somatostatin and the immune and haematopoietic system; a review. Eur J Clin Investig 1994;24:91–9.
Shih W-J, Samayoa L. Tc-99m depreotide detecting malignant pulmonary nodules. Histopathologic correlation with semiquantitative tumour-to-normal lung ratio. Clin Nucl Med 2004;29:171–6.
Bushnell D, Menda Y, Madsen M, Link B, Kahn D, Truhlar S, et al. 99m-Tc-depreotide tumour uptake in patients with non-Hodgkin’s lymphoma. Nucl Med Commun 2004;25:839–43.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Danielsson, R., Bååth, M., Svensson, L. et al. Imaging of regional lymph node metastases with 99mTc-depreotide in patients with lung cancer. Eur J Nucl Med Mol Imaging 32, 925–931 (2005). https://doi.org/10.1007/s00259-005-1800-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-005-1800-5